The Belgian Competition Authority, which contributes to implementing Belgium’s competition policy by addressing anticompetitive practices, announced that it is conducting inspections of some drug makers suspected of having implemented “restrictive practices aimed at limiting, delaying or even preventing the entry into the market or the expansion of biosimilar medicines competing with existing medicines."
In the United States, biosimilars have faced numerous challenges, and some of those—as related to exclusionary contracts, bundled rebates, and multiproduct bundling practices related to innovator products—have even become the subject of antitrust scrutiny and related lawsuits.
While those problems are particularly apparent in the US context, international activity shows that they are not unique to the United States; this month, the Belgian Competition Authority, which contributes to implementing Belgium’s competition policy by addressing anticompetitive practices, announced that it is conducting inspections of some drug makers.
The on-the-premises inspections are taking place at companies suspected of having implemented “restrictive practices aimed at limiting, delaying or even preventing the entry into the market or the expansion of biosimilar medicines competing with existing medicines,” the agency said in a statement, and these practices could represent infringements of the law.
The duration of the Belgian investigation into these companies will depend, said the authority, on factors including the degree of complexity of the case, drug makers’ cooperation with the authority, and the companies’ exercise of their rights of defense.
According to the Belgian newspaper De Morgen, the investigation includes assessing brand-name biologics that continue to be preferred even after biosimilars become commercially available. Other concerns include whether brand-name biologics makers are using the threat of withholding discounts to keep hospital systems from switching to biosimilars.
Improving the Belgian biosimilars market is important, say stakeholders, as the market has remained relatively small in comparison to other European countries. According to a recent KPMG report, some of the reasons for Belgium’s comparatively low biosimilar uptake include tender criteria that often favor innovator drugs, such as distance to the manufacturing plant, speed of delivery, or availability of single-dose packaging.
According to the report’s authors, “physicians might have an incentive to add these originator-favoring award-criteria to the tender procedures, as the outcome of the tender may affect their personal grants and personal sponsorships from the manufacturers which produce the originator medicines.”
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
2 Commerce Drive
Cranbury, NJ 08512